<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560739</url>
  </required_header>
  <id_info>
    <org_study_id>COMB157G2102</org_study_id>
    <nct_id>NCT03560739</nct_id>
  </id_info>
  <brief_title>A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients</brief_title>
  <official_title>A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to demonstrate pharmacokinetic bioequivalence of
      ofatumumab injected by Pre-filled Syringe (PFS) versus Auto-Injector (AI) devices and thereby
      establish a bridge between the ongoing Phase 3 program and the to-be-marketed drug-device
      combinations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Characterization of the pharmacokinetics of ofatumumab administered via the PFS used
      inclinical trials and the to-be-marketed autoinjector at the clinical dose of 20 mg will be
      conducted after an initial depletion of CD20 positive B-cells. Comparing the ofatumumab
      pharmacokinetics between the two drug-device combinations only after the induction period is
      expected to reduce initial high variability due to target-mediated clearance. This ensures a
      more stable baseline for PK comparison in a parallel group study design and reflects the
      clinical situation where systemic concentrations are at steady-state. In order to justify the
      resulting longterm B-cell depletion, a PK comparability study between the PFS and the AI can
      only be conducted in MS patients rather than in healthy subjects to balance the risk/benefit
      and to obtain PK data from the relevant patient population. In order for patients to obtain a
      clinical benefit from participation in the study, continued treatment with ofatumumab will be
      offered to all eligible patients through enrollment into the open-label Phase 3 extension
      study (separate protocol, COMB157G2399).

      A secondary objective of the study is to characterize the pharmacokinetics following
      subcutaneous administration of ofatumumab to either the abdominal region or the thigh which
      are two injections sites allowed in the Phase 3 study and planned for inclusion in the label.
      Another secondary objective is assessment of immunogenicity during the 12 weeks duration of
      the study addressing potential differences in ofatumumab anti-drug antibody formation between
      the PFS and AI devices as well as between abdomen and thigh injection sites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Actual">May 5, 2020</completion_date>
  <primary_completion_date type="Actual">August 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>To address the primary objective of testing bioequivalence at dosing interval after Week 8 between Pre-filled Syringe (PFS) and Auto-Injector (AI), the primary analysis involves the two groups (PFS (abdomen) and AI (abdomen)). Further the pharmacokinetcs of ofatumumab will be compared between using the thigh or abdomen for injections.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUCtau) for PFS and AI devices when administered to abdomen</measure>
    <time_frame>8 weeks to 12 weeks</time_frame>
    <description>Bioequivalence (AUCtau) will be measured over the time period from 8-12 weeks comparing the pre-filled syringe (PFS) and autoinjector (AI) devices both administered to the abdomen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) for PFS and AI when administered to abdomen</measure>
    <time_frame>8 weeks to12 weeks</time_frame>
    <description>Bioequivalence (Cmax) will be measured over the time period from 8-12 weeks comparing the PFS and autoinjector devices both administered to the abdomen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of AUCtau for PFS and AI devices when administered to abdomen or thigh</measure>
    <time_frame>8 weeks to 12 weeks</time_frame>
    <description>Plasma concentration for AUCtau for time interval of 8 weeks to 12 weeks following subcutaneous administration of ofatumumab via PFS or AI to either the abdominal region or the thigh</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Cmax for PFS and AI devices when administered to abdomen or thigh</measure>
    <time_frame>8 weeks to 12 weeks</time_frame>
    <description>Plasma concentration for Cmax for time interval of 8 weeks to 12 weeks following subcutaneous administration of ofatumumab via PFS or AI to either the abdominal region or the thigh</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with anti-ofatumumab antibodies</measure>
    <time_frame>Baseline, weeks 4, 8, 12 and overall</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>OMB 20mg PFS abdomen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on abdomen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMB 20mg AI abdomen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on abdomen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMB 20mg PFS thigh</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on thigh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMB 20mg AI thigh</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on thigh</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ofatumumab with PRF</intervention_name>
    <description>ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)</description>
    <arm_group_label>OMB 20mg PFS abdomen</arm_group_label>
    <arm_group_label>OMB 20mg PFS thigh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ofatumumab with AI</intervention_name>
    <description>ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)</description>
    <arm_group_label>OMB 20mg AI abdomen</arm_group_label>
    <arm_group_label>OMB 20mg AI thigh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of multiple sclerosis (MS)

          -  Relapsing MS: relapsing-remitting course (RRMS), or Secondary progressive (SPMS)
             course

          -  EDSS score of 0 to 5.5

          -  Documentation of at least: 1 relapse during the previous year OR 2 relapses during the
             previous 2 years prior to Screening OR a positive Gd-enhancing MRI scan during the
             year prior to randomization.

          -  Neurologically stable within 1 month prior to randomization

        Exclusion Criteria:

          -  Patients with primary progressive MS or SPMS without disease activity

          -  Disease duration of more than 10 years in patients with EDSS score of 2 or less

          -  Patients with an active chronic disease of the immune system other than MS

          -  Patients with active systemic bacterial, viral or fungal infections, or known to have
             AIDS or to test positive for HIV antibody at Screening

          -  Patients with neurological findings consistent with Progressive Multifocal
             Leukoencephalopathy (PML), or confirmed PML
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basalt</city>
        <state>Colorado</state>
        <zip>81621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ozark</city>
        <state>Missouri</state>
        <zip>65721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1413</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Havirov</city>
        <state>Czech Republic</state>
        <zip>736 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teplice</city>
        <state>Czech Republic</state>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hradec Kralove</city>
        <state>CZE</state>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <state>LV</state>
        <zip>LV-1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LTU</state>
        <zip>LT 50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Castilleja de la cuesta</city>
        <state>Sevilla</state>
        <zip>41950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <disposition_first_submitted>November 6, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>December 30, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 2, 2020</disposition_first_posted>
  <last_update_submitted>July 19, 2020</last_update_submitted>
  <last_update_submitted_qc>July 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Multiple Sclerosis</keyword>
  <keyword>Relapsing-remitting Multiple Sclerosis</keyword>
  <keyword>Secondary progressive Multiple Sclerosis</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Neurofilament light chain</keyword>
  <keyword>Pre-filled Syringe</keyword>
  <keyword>Auto-injector</keyword>
  <keyword>adult</keyword>
  <keyword>AI</keyword>
  <keyword>PFS</keyword>
  <keyword>OMB157</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
    <ipd_url>https://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

